Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

BAYESIAN ANALYSIS OF BASELINE RISK OF CIN2 AND ≥CIN3 BY HPV GENOTYPE IN A EUROPEAN REFERRAL COHORT

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Harvard

Bonde, J, Bottari, F, Parvu, V, Pedersen, H, Yanson, K, Iacobone, AD, Kodsi, S, Landoni, F, Vaughan, L, Ejegod, DM & Sandri, MT 2019, 'BAYESIAN ANALYSIS OF BASELINE RISK OF CIN2 AND ≥CIN3 BY HPV GENOTYPE IN A EUROPEAN REFERRAL COHORT' International Journal of Cancer, bind 145, nr. 4, s. 1033-1041. https://doi.org/10.1002/ijc.32291

APA

CBE

MLA

Vancouver

Author

Bonde, Jesper ; Bottari, Fabio ; Parvu, Valentin ; Pedersen, Helle ; Yanson, Karen ; Iacobone, Anna Daniela ; Kodsi, Salma ; Landoni, Fabio ; Vaughan, Laurence ; Ejegod, Ditte Møller ; Sandri, Maria Teresa. / BAYESIAN ANALYSIS OF BASELINE RISK OF CIN2 AND ≥CIN3 BY HPV GENOTYPE IN A EUROPEAN REFERRAL COHORT. I: International Journal of Cancer. 2019 ; Bind 145, Nr. 4. s. 1033-1041.

Bibtex

@article{c1271a10772647518079ab6ee3a27bdf,
title = "BAYESIAN ANALYSIS OF BASELINE RISK OF CIN2 AND ≥CIN3 BY HPV GENOTYPE IN A EUROPEAN REFERRAL COHORT",
abstract = "Whereas HPV16 and HPV18 have been the focus in current risk-based cervical cancer screening algorithms using HPV genotype information, mounting evidence suggests that oncogenic HPV types such as HPV31, 33, 52 and 58 pose a ≥CIN3 risk equivalent to or greater than that of HPV18, and the combined risk of HPV31 and HPV33 rivals even HPV16 in women above 30 years of age. Here, we evaluate the baseline risk of CIN2 and CIN3 by genotype in a colposcopy referral population from Denmark and Italy. In total, 655 women were enrolled upon a referral to colposcopy after a positive screening sample. All samples were HPV analyzed using Onclarity HPV assay with extended genotyping and combined with the histology outcomes, a Bayesian probability modeling was used to determine the risk per genotype assessed. The combined data for this referral population showed that the ≥CIN2 risk of HPV16 was 69.1{\%}, HPV31 at 63.3{\%}, HPV33/58 at 52.7{\%}, HPV18 at 46.6{\%} and HPV52 at 40.8{\%}. For ≥CIN3, the risks were 44.3{\%}, 38.5{\%}, 36.8{\%}, 30.9{\%} and 16.8{\%} for HPV16, HPV31, HPV18, HPV33/58 and HPV52, respectively, indicating that the baseline risk of disease arising from HPV16 is, not surprisingly, the highest among the oncogenic HPV genotypes. We find that the HPV genotype-specific ≥CIN2 and ≥CIN3 risk-patterns are so distinct that, for example, 35/39/68 and 56/59/66 should be considered only for low intensive follow-up, thereby proposing active use of this information in triage strategies for screening HPV-positive women.",
author = "Jesper Bonde and Fabio Bottari and Valentin Parvu and Helle Pedersen and Karen Yanson and Iacobone, {Anna Daniela} and Salma Kodsi and Fabio Landoni and Laurence Vaughan and Ejegod, {Ditte M{\o}ller} and Sandri, {Maria Teresa}",
note = "{\circledC} 2019 The Authors. International Journal of Cancer published by John Wiley & Sons Ltd on behalf of UICC.",
year = "2019",
month = "8",
day = "15",
doi = "10.1002/ijc.32291",
language = "English",
volume = "145",
pages = "1033--1041",
journal = "International Journal of Cancer",
issn = "0020-7136",
publisher = "JohnWiley & Sons, Inc",
number = "4",

}

RIS

TY - JOUR

T1 - BAYESIAN ANALYSIS OF BASELINE RISK OF CIN2 AND ≥CIN3 BY HPV GENOTYPE IN A EUROPEAN REFERRAL COHORT

AU - Bonde, Jesper

AU - Bottari, Fabio

AU - Parvu, Valentin

AU - Pedersen, Helle

AU - Yanson, Karen

AU - Iacobone, Anna Daniela

AU - Kodsi, Salma

AU - Landoni, Fabio

AU - Vaughan, Laurence

AU - Ejegod, Ditte Møller

AU - Sandri, Maria Teresa

N1 - © 2019 The Authors. International Journal of Cancer published by John Wiley & Sons Ltd on behalf of UICC.

PY - 2019/8/15

Y1 - 2019/8/15

N2 - Whereas HPV16 and HPV18 have been the focus in current risk-based cervical cancer screening algorithms using HPV genotype information, mounting evidence suggests that oncogenic HPV types such as HPV31, 33, 52 and 58 pose a ≥CIN3 risk equivalent to or greater than that of HPV18, and the combined risk of HPV31 and HPV33 rivals even HPV16 in women above 30 years of age. Here, we evaluate the baseline risk of CIN2 and CIN3 by genotype in a colposcopy referral population from Denmark and Italy. In total, 655 women were enrolled upon a referral to colposcopy after a positive screening sample. All samples were HPV analyzed using Onclarity HPV assay with extended genotyping and combined with the histology outcomes, a Bayesian probability modeling was used to determine the risk per genotype assessed. The combined data for this referral population showed that the ≥CIN2 risk of HPV16 was 69.1%, HPV31 at 63.3%, HPV33/58 at 52.7%, HPV18 at 46.6% and HPV52 at 40.8%. For ≥CIN3, the risks were 44.3%, 38.5%, 36.8%, 30.9% and 16.8% for HPV16, HPV31, HPV18, HPV33/58 and HPV52, respectively, indicating that the baseline risk of disease arising from HPV16 is, not surprisingly, the highest among the oncogenic HPV genotypes. We find that the HPV genotype-specific ≥CIN2 and ≥CIN3 risk-patterns are so distinct that, for example, 35/39/68 and 56/59/66 should be considered only for low intensive follow-up, thereby proposing active use of this information in triage strategies for screening HPV-positive women.

AB - Whereas HPV16 and HPV18 have been the focus in current risk-based cervical cancer screening algorithms using HPV genotype information, mounting evidence suggests that oncogenic HPV types such as HPV31, 33, 52 and 58 pose a ≥CIN3 risk equivalent to or greater than that of HPV18, and the combined risk of HPV31 and HPV33 rivals even HPV16 in women above 30 years of age. Here, we evaluate the baseline risk of CIN2 and CIN3 by genotype in a colposcopy referral population from Denmark and Italy. In total, 655 women were enrolled upon a referral to colposcopy after a positive screening sample. All samples were HPV analyzed using Onclarity HPV assay with extended genotyping and combined with the histology outcomes, a Bayesian probability modeling was used to determine the risk per genotype assessed. The combined data for this referral population showed that the ≥CIN2 risk of HPV16 was 69.1%, HPV31 at 63.3%, HPV33/58 at 52.7%, HPV18 at 46.6% and HPV52 at 40.8%. For ≥CIN3, the risks were 44.3%, 38.5%, 36.8%, 30.9% and 16.8% for HPV16, HPV31, HPV18, HPV33/58 and HPV52, respectively, indicating that the baseline risk of disease arising from HPV16 is, not surprisingly, the highest among the oncogenic HPV genotypes. We find that the HPV genotype-specific ≥CIN2 and ≥CIN3 risk-patterns are so distinct that, for example, 35/39/68 and 56/59/66 should be considered only for low intensive follow-up, thereby proposing active use of this information in triage strategies for screening HPV-positive women.

UR - http://www.scopus.com/inward/record.url?scp=85065159513&partnerID=8YFLogxK

U2 - 10.1002/ijc.32291

DO - 10.1002/ijc.32291

M3 - Journal article

VL - 145

SP - 1033

EP - 1041

JO - International Journal of Cancer

JF - International Journal of Cancer

SN - 0020-7136

IS - 4

ER -

ID: 56861877